Cargando…

Risk of Thrombosis in Adult Philadelphia-Positive ALL Treated with an Asparaginase-Free ALL Regimen

Background: venous thromboembolism (VTE) is a well-known complication in adults with acute lymphoblastic leukemia (ALL), especially in patients treated with asparaginase (ASNase)-including regiments. However, VTE risk in adult Philadelphia-positive ALL (Ph+ve ALL) patients treated with non-hyperCVAD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Ruiqi, Liu, Xing, Law, Arjun D., Kanfar, Solaf, Maze, Dawn, Chan, Steven M., Gupta, Vikas, Yee, Karen W., Minden, Mark D., Schimmer, Aaron D., Schuh, Andre C., McNamara, Caroline J., Murphy, Tracy, Xu, Anna, Falcone, Umberto, Seki, Jack, Sibai, Hassan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816186/ https://www.ncbi.nlm.nih.gov/pubmed/33704181 http://dx.doi.org/10.3390/curroncol28010016

Ejemplares similares

Safety of re‐challenging adults with acute lymphoblastic leukemia with PEG‐asparaginase‐induced severe hypertriglyceridemia when treated with a pediatric‐inspired regimen
por: Al Nabhani, Ibrahim, et al.
Publicado: (2022)

P385: COMPARISON OF CLINICAL OUTCOMES AND ADVERSE EVENTS IN OLDER ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH NATIVE VS PEGYLATED ASPARAGINASE
por: Agustina Perusini, Maria, et al.
Publicado: (2023)

Measurable residual disease monitoring provides insufficient lead-time to prevent morphological relapse in the majority of patients with core-binding factor acute myeloid leukemia
por: Puckrin, Robert, et al.
Publicado: (2020)

Allergic Reactions to E. coli Asparaginase are Associated with Decreased Asparaginase Activity in an Indonesian Pediatric Population with ALL
por: Sari, Nur Melani, et al.
Publicado: (2023)

PB1757: VARIANT PHILADELPHIA CHROMOSOME IN ALL
por: Bouayed Abdelmoula, N., et al.
Publicado: (2022)

P1020: SCREENING FOR PORTAL HYPERTENSION IN PATIENTS WITH PHILADELPHIA NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
por: Davidson, M., et al.
Publicado: (2022)

Rhizobium etli asparaginase II: An alternative for acute lymphoblastic leukemia (ALL) treatment
por: Huerta-Saquero, Alejandro, et al.
Publicado: (2013)

Association of allele-specific methylation of the ASNS gene with asparaginase sensitivity and prognosis in T-ALL
por: Akahane, Koshi, et al.
Publicado: (2022)

Clinical Utility of Next-generation Sequencing in the Management of Myeloproliferative Neoplasms: A Single-Center Experience
por: Alduaij, Waleed, et al.
Publicado: (2018)

The Effect of Combination of Steroid and L-Asparaginase on Hyperglycemia in Children with Acute Lymphoblastic Leukemia (ALL)
por: Aisyi, Mururul, et al.
Publicado: (2019)

What Is the Role of HSCT in Philadelphia-Chromosome–Positive and Philadelphia-Chromosome–Like ALL in the Tyrosine Kinase Inhibitor Era?
por: Vettenranta, Kim, et al.
Publicado: (2022)

ALL blasts drive primary mesenchymal stromal cells to increase asparagine availability during asparaginase treatment
por: Chiu, Martina, et al.
Publicado: (2021)

The optimal use of PEG-Asparaginase in relapsed ALL—lessons from the ALLR3 Clinical Trial
por: Masurekar, A, et al.
Publicado: (2014)

High Incidence of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia (Ph-like ALL) in Older Adults with B-ALL
por: Tasian, Sarah K, et al.
Publicado: (2016)

Whole-exome sequencing identified genetic risk factors for asparaginase-related complications in childhood ALL patients
por: Abaji, Rachid, et al.
Publicado: (2017)

Increasing completion of asparaginase treatment in childhood acute lymphoblastic leukaemia (ALL): summary of an expert panel discussion
por: Baruchel, André, et al.
Publicado: (2020)

Ruxolitinib/nilotinib cotreatment inhibits leukemia-propagating cells in Philadelphia chromosome-positive ALL
por: Kong, Yuan, et al.
Publicado: (2017)

Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open–Cancer Horizons roundtable discussion
por: Burke, Patrick W, et al.
Publicado: (2020)

Asparaginase enzyme activity levels and toxicity in childhood acute lymphoblastic leukemia: a NOPHO ALL2008 study
por: Lynggaard, Line Stensig, et al.
Publicado: (2022)

Debrief it all: a tool for inclusion of Safety-II
por: Bentley, Suzanne K., et al.
Publicado: (2021)

Biallelic disruption of DDX41 activity is associated with distinct genomic and immunophenotypic hallmarks in acute leukemia
por: Tierens, Anne, et al.
Publicado: (2023)

Leukemia propagating cells in Philadelphia chromosome-positive ALL: a resistant phenotype with an adverse prognosis
por: El-Menshawy, Nadia, et al.
Publicado: (2018)

Philadelphia-positive (PH+) acute lymphoblastic leukemia (ALL): developing strategies for curing this stubborn disease
por: Liam, Christopher Chin Keong, et al.
Publicado: (2022)

Synergistic Cytotoxic Effect of L-Asparaginase Combined with Decitabine as a Demethylating Agent in Pediatric T-ALL, with Specific Epigenetic Signature
por: Serravalle, Salvatore, et al.
Publicado: (2016)

Affordable and Safe Health Care for All Children: Lessons Learned from the Use of Peg-asparaginase in a Developing Country
por: Jayaraman, Dhaarani, et al.
Publicado: (2017)

The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 study
por: Aldoss, Ibrahim, et al.
Publicado: (2022)

Utility of ASNS gene methylation evaluated with the HPLC method as a pharmacogenomic biomarker to predict asparaginase sensitivity in BCP-ALL
por: Watanabe, Atsushi, et al.
Publicado: (2023)

Are we conSTRucting the best treatment regimens for all patients with HIV infection?
por: Friday, D, et al.
Publicado: (2012)

Osteolytic lesion in polycythemia vera: First report and review of literature
por: Cheung, Verna, et al.
Publicado: (2022)

Allergic Contact Dermatitis From Transient Formaldehyde Exposure in a Traveler: Are All Backpacks Created Equal?
por: Valdes, Flavia, et al.
Publicado: (2020)

MRD-Based Therapeutic Decisions in Genetically Defined Subsets of Adolescents and Young Adult Philadelphia-Negative ALL
por: Tosi, Manuela, et al.
Publicado: (2021)

Aggressive Regimens for Multidrug-Resistant Tuberculosis Decrease All-Cause Mortality
por: Mitnick, Carole D., et al.
Publicado: (2013)

Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease
por: Kaloyannidis, Panayotis, et al.
Publicado: (2018)

ANTIBODY RESPONSES AND SAFETY OF THE COMMERCIALLY AVAILABLE VACCINES AGAINST SARS-COV-2 VIRUS IN ALLOGRAFTED PATIENTS: REAL WORLD DATA FROM A SINGLE CENTER
por: Kaloyannidis, Panayotis, et al.
Publicado: (2022)

PB1742: FEASIBILITY AND EFFICACY OF A PEG-ASPARAGINASE-BASED TREATMENT PROTOCOL IN ELDERLY PHILADELPHIA-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS
por: Vernarecci, Chiara, et al.
Publicado: (2023)

PEG-asparaginase in BFM-90 regimen improves outcomes in adults with newly diagnosed lymphoblastic lymphoma
por: Zheng, Wen, et al.
Publicado: (2017)

Asparaginase-Associated Pancreatitis in Acute Lymphoblastic Leukemia: Results From the NOPHO ALL2008 Treatment of Patients 1-45 Years of Age
por: Rank, Cecilie U., et al.
Publicado: (2020)

Saudi Arabian CML patient with a novel four‐way translocation at t(9;22;5;2)(q34;q11.2;p13;q44)
por: Dridi, Walid, et al.
Publicado: (2022)

Towards all-oral and shorter treatment regimens for drug-resistant tuberculosis
por: Weyer, Karin, et al.
Publicado: (2018)

The adjuvant regimen for resected EGFR mutated patients: the “same-for-all-therapy” or not?
por: Gridelli, Cesare, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cem94uu1lvqqpq9npoa96v9ncg